# Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy

> **NCT07056010** · NA · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **PROCEDURE:** curative minimally invasive gastrectomy with D2+PAND lymphadenectomy

## Key facts

- **NCT ID:** NCT07056010
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2025-11-25
- **Final completion:** 2028-11-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07056010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07056010, "Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07056010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*